GSK kills one of Barron’s early darlings, axing two synthetic lethal programs and Epizyme pact Pfizer tidies up pipeline while eyeing external science to add $25B in revenue by 2030 Checkmate plucks BMS exec Bash to be new CEO Rivus throws down mid-stage liver fat data on quest to climb NASH mountain Chasing Novartis and Roche, Ventus banks $140M to take inflammatory disease drug into the clinic Avrobio hopes to chart rebound after Fabry setback with lysosomal storage disorder gene therapy Seismic emerges with $101M, Harvard billionaire founder and leadership team fresh off $1.9B exit Axsome’s migraine drug finally slated for FDA inspection, but investors want to know about stalled depression therapy J&J pauses COVID-19 vaccine production at Dutch plant in temporary pivot to RSV shot: NYT GN’s Jabra sends self-fitting hearing aids to market for $799 ahead of FDA over-the-counter ruling CVS Health beats the Street with $1.3B in profit for Q4 Eli Lilly, Innovent's PD-1 in troubled waters as FDA review, oncology chief's comments portend likely rejection Featured Story | By Nick Paul Taylor Shortly after becoming GlaxoSmithKline’s chief scientific officer, Hal Barron highlighted GSK3326595 as one of four early-stage cancer programs to watch. Today, with Barron’s time at the company nearing its end, GSK axed the PRMT5 inhibitor and sibling molecule GSK3368715 from its pipeline. read more |
| |
|---|
|
Top Stories By Kyle LaHucik Pfizer is doing a little house cleaning of its pipeline, but not to worry. CEO Albert Bourla is expecting to bring on external science that could help reap "at least $25 billion of risk-adjusted revenues" by 2030. read more By Max Bayer Checkmate Pharmaceuticals has hired Bristol Myers Squibb SVP Alan Bash as president and CEO, completing a more than three-month search for someone to fill the top post. The company hopes Bash will be able to replicate his success overseeing the U.S. launch of Opdivo. read more By Annalee Armstrong Considering NASH drug development has stumped companies big and small, can newcomer Rivus Pharmaceuticals move the needle? The Charlottesville, Va.-based company hopes so, and is out today with data on its lead candidate showing a reduction in liver fat, a key hallmark of NASH, or non-alcoholic steatohepatitis. read more By Nick Paul Taylor The money keeps flowing into Ventus Therapeutics. Just 10 months after raising one mega-round, the undruggable target specialist has banked a further $140 million as it prepares to file three INDs next year. read more By Kyle LaHucik Avrobio's gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year after infusion. It's a small patient group, but Avrobio hopes it will be big enough to chart a rebound after ditching a gene therapy program for Fabry disease last month. read more By Kyle LaHucik With the help of Harvard billionaire professor Timothy Springer, Ph.D., and other academic founders, Jo Viney and Alan Crane are now putting up the open sign for Seismic Therapeutic with $101 million to start off. read more By Max Bayer The FDA will in fact be able to inspect Axsome’s manufacturing facility for its migraine drug by the decision date as the agency gets these crucial inspections back on track following COVID disruptions. read more By Fraiser Kansteiner The news that Johnson & Johnson stopped making its pandemic vaccine at a key European plant came as a bit of a shock. Not to worry, though, the company says—the production pause was all part of the plan and should be over by next month. read more By Andrea Park The Enhance Plus earbuds have been cleared by the FDA as self-fitting hearing aids. read more By Paige Minemyer CVS Health posted $1.3 billion in profit for the fourth quarter of 2021, up from $973 million in the prior-year quarter. read more By Angus Liu An FDA rebuff looks almost certain for Eli Lilly and partner Innovent Biologics’ PD-1 inhibitor Tyvyt as an overwhelmingly negative internal FDA review ahead of an advisory committee meeting suggests the agency is unwilling to consider a drug solely based on clinical data from China. read more Resources Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Blue Matter, strategic consultants in the life sciences What’s in store for the CNS therapeutics market in 2022? This paper looks ahead in Alzheimer’s, Parkinson’s, DMD, psychiatric disorders, pain, and more. Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Fierce Drug Safety Summit March 8-9, 2022 | Virtual Fierce BD&L Summit for Life Sciences March 15-16, 2022 | San Francisco, CA Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Fierce Medical Affairs Strategic Summit (MASS) East April 12-14, 2022 | New Brunswick, NJ Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Leaders in Life Sciences Forum May 24, 2022 | Complimentary Virtual Event Fierce Health IT Summit May 24, 2022 | Virtual Event Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Pharma PR & Communications Summit West June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Next-Gen Week June 29-30, 2022 | Virtual Event Fierce Pharma PR & Communications Summit July 2022 | Location TBD (NYC Metro Area) Fierce MedTech Summit August 8-9, 2022 | Minneapolis, MN Fierce Biotech Summit September 13-14, 2022 | Boston, MA Promotional Review Committee Compliance and Best Practices Summit West (PRC West) September 2022 | San Diego, CA Medical Affairs Strategic Summit (MASS West) September 2022 | San Diego, CA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Marketing Awards October 19, 2022 | Philadelphia, PA Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Fierce European Trial Master File Summit October 31- November 2, 2022 | London Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce Diversity, Equity & Inclusion Forum November 15-16, 2022 | Virtual Event Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce New Product Planning Summit November 30 - December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 